STSA News and Press, Satsuma Pharmaceuticals Inc. From 06/16/21

Satsuma Pharmaceuticals (STSA) announces positive pharmacokinetic, tolerability and safety results from a Phase 1 trial of migraine treatment STS101.Shares up more than 18% post market.The Phase 1 data showed that all three dose strengths (5.2 mg and two higher dose strengths) ...

- All three dose strengths of STS101, administered with improved 2 nd -generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT Phase 3 efficacy trial to evaluate STS101 5.2 mg in the acute treatment of mi...

Satsuma Pharmaceuticals (STSA): Q1 GAAP EPS of -$0.48 misses by $0.07.$133 million in cash, cash equivalents and marketable securities as of March 31, 2021.Press Release For further details see: Satsuma Pharmaceuticals EPS misses by $0.07

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022- -Results expected in Q2 from ongoing Phase 1 trial to inform dose selection for Phase 3- -$133 million in cash, cash equivalents and market...

Gainers: [[PFMT]] +13.7%. [[MVIS]] +4.3%. [[CLSD]] +4.2%. [[FLXN]] +3.7%. [[FOLD]] +3.7%.Losers: [[STSA]] -9.9%. [[CNTG]] -7.9%. [[XELB]] -6.2%. [[CLAR]] -5.9%. [[DISCK]] -5.2%. For further details see: PFMT, MVIS, STSA and XELB among after-hours movers

Citi expects makers of healthcare equipment to recover as vaccinations drive down COVID-19 infections and procedures return. Surging Invitae after Softbank-backed investment gets another boost as Oppenheimer upgrades the stock. Equipment makers to benefit from recovery trade Citi analysts are...

Satsuma Pharmaceuticals (STSA): Q4 GAAP EPS of -$0.72 misses by $0.19.Cash, cash equivalents and marketable securities of $68.2M.Press Release For further details see: Satsuma Pharmaceuticals EPS misses by $0.19

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022 Closed $80 million private placement of common stock financing with new and existing investors Cas...

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a corporate overview at the 31 st Annual Oppenheimer Healthcare Conference on March ...

Satsuma's lead and only candidate STS101 targeting treatment of acute migraines failed a pivotal trial in September last year. After a long silence, management has announced that it will launch a 2nd pivotal trial sometime in 2022, and has taken learnings from the 1st trial is confide...